We are focused on developing disease-modifying therapies that address unmet medical needs of patients and families suffering from rare diseases with the goal of making a positive difference in their lives.
Matthew Gantz, President and Chief Executive Officer
Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and the Oliveira family. Used with permission.
Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial
Read MoreCastle Creek Biosciences' D-Fi To Be Manufactured At In-House cGMP
Read MoreCompany manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area
Read MoreStudy targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.
Read More